Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$16.85 USD
+0.69 (4.27%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.84 -0.01 (-0.06%) 6:32 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.85 USD
+0.69 (4.27%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.84 -0.01 (-0.06%) 6:32 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
by Zacks Equity Research
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
by Zacks Equity Research
The FDA bestows RMAT designation to Cartesian's (RNAC) lead pipeline candidate, Descartes-08, for treating myasthenia gravis. Shares rise.
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 141% upside potential for Cartesian Therapeutics, Inc. (RNAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Cartesian Therapeutics, Inc. (RNAC) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -1,100% and 5.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?